Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Azerbaijan: Human H5 deaths confirmed after diagnostic capacity shortcomings:

This article was originally published in Clinica

Executive Summary

The health ministry of Azerbaijan was forced to request significant laboratory support in investigating a cluster of 11 suspected avian flu cases, including at least three deaths, which have now been confirmed as due to the H5 virus subtype. The situation has highlighted wider shortcomings in the country's diagnostic services and supplies. "The response of the health ministry has been prompt and efficient, but hampered by the lack of some essential equipment and supplies, and an inadequate diagnostic capacity," said the WHO. H5 was confirmed using a portable PCR field laboratory provided by the US Naval Medical Research Unit 3 (NAMRU-3), based in Cairo, Egypt. "NAMRU-3 serves as a collaborating centre for emerging infections - test results are considered reliable," the WHO explained. However, samples are undergoing diagnostic verification and further analysis in the UK.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT051140

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel